AFP and hepatocellular carcinoma: As the most established biomarker in HCC, higher serum AFP levels have been associated with increased tumor aggressiveness (e.g., worse tumor differentiation [22], increased incidence of microvascular invasion [23], macrotrabecular-massive subtype [20, 24], proliferative HCC [25]), and worse posttreatment prognosis [26–28].